Hugh Laverty

Hugh Laverty, PhD

Executive Director ad interim

The Innovative Health Initiative

Mr. Hugh Laverty is currently the Executive Director ad interim of the Innovative Health Initiative (IHI).

In addition, he is the Head of Scientific Operations (HoSO) at IHI where he leads a team of scientific and financial officers responsible for the operational activities of the organisation. In his role as (HoSO) he is responsible for the overall planning, management and monitoring of calls for proposals and evaluations leading to projects/grant agreements, as well as the management of the projects themselves. He held the same position in IMI2 between 2015 and 2021.  He joined IMI as a Senior Scientific Project Manager in 2011 managing specific projects and overseeing IMI’s engagement with Small and Medium Enterprises (SMEs).

Before joining IMI, he worked as Industry Programme Manager at the Centre for Drug Safety Sciences at the University of Liverpool, UK. He also has extensive experience in the Biotech sector having spent nearly 10 years working in an SME identifying and developing recombinant proteins as novel therapeutics for the prevention of dermal scarring.

Trained as a Molecular biologist he has a PhD in gene cloning and developmental biology with an interest in a wide range of scientific areas and research questions.


Other speakers in 2022

Thomas Bols


Thomas Bols

Head of Government Affairs and Patient Advocacy, EMEA & APAC at PTC Therapeutics, Inc.
Member of the Board of EuropaBio
Sibilia Quilici


Sibilia Quilici (MBA, MSc)

Executive Director of Vaccines Europe
EFPIA - European Federation of Pharmaceutical Industries and Associations
Stanimir Hasurdzhiev


Stanimir Hasardzhiev, Dr.

Secretary General - Patient Access Partnership (PACT) / Secretary General - CEE4HEALTH / Genereal Director - National Patient Organisation (NPO) / Chairperson - Bulgarian Association for Personalized Medicine (BAPEMED)
Skip to content